Breaks Categories: News

FridayFeb 24, 2017 11:13 am

NetworkNewsBreaks – Intellipharmaceutics International, Inc. (NASDAQ: IPCI) Shares Higher on FDA Approval of Two Strengths of Generic Glucophage® XR

Intellipharmaceutics International (NASDAQ: IPCI) shares were up 27% this morning following news that it has received final approval for its abbreviated new drug application (ANDA) for metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths from the U.S. Food and Drug Administration (FDA). Metformin hydrochloride extended release is a generic equivalent for the matching strengths of the branded product Glucophage® XR, which is sold in the United States by Bristol-Myers Squibb and indicated for use in the management of type 2 diabetes. "FDA approval of our application for a generic version of Glucophage® XR provides further…

Continue Reading

ThursdayFeb 23, 2017 11:28 am

NetworkNewsBreaks – MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) Receives Regulatory Green Light for Clinical Trial of Pancreatic Cancer Candidate

MabVax Therapeutics (NASDAQ: MBVX) is trading higher after announcing it has received authorization from the FDA for the initiation of a phase I clinical trial with MVT-1075 as a therapeutic treatment for pancreatic cancer. MVT-1075 is the company's novel, fully human antibody radioimmunotherapy. In this initial phase I trial the company plans to evaluate the safety, dosimetry, and pharmacokinetics of MVT-1075 with patient disease status evaluated based on tumor measurements using RECIST 1.1 criteria. The company intends to initiate the phase I clinical trial in the first half of 2017. "We are executing on the development strategy we have outlined…

Continue Reading

ThursdayFeb 23, 2017 11:19 am

NetworkNewsBreaks – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Shares Tumble on Disappointing Phase 3 Clinical Trial of Leukemia Candidate

Shares of Cyclacel Pharmaceuticals (NASDAQ: CYCC) are down more than 15% after the company reported that its lead candidate failed to meet its primary endpoint in a phase 3 study of elderly patients with acute myeloid leukemia (AML). The trial did not meet its primary endpoint of demonstrating statistically significant improvement in overall survival (OS) for the experimental arm versus an active control. The secondary endpoint, an improved rate of complete remission (CR), was observed in patients who had discontinued therapy at the time of analysis. Full results from the SEAMLESS study will be submitted for presentation at an upcoming…

Continue Reading

WednesdayFeb 22, 2017 10:54 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Presenting at SeeThruEquity Conference Later Today

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its management team will be presenting at the SeeThruEquity Conference in South Beach, Miami, later today. The presentation is scheduled to begin at 1:30 pm on February 22, 2017. Copies of presentation materials are currently available at www.ChineseInvestors.com. In addition to this afternoon’s presentation, the company will also be holding meetings with potential investors on February 23-24 alongside the team from WallStreet Research™. A corporate profile covering CIIX created by WallStreet Research is available for download at www.WallStreetResearch.org. To view the full press release, visit http://nnw.fm/ANC7k About ChineseInvestors.com Founded…

Continue Reading

TuesdayFeb 21, 2017 10:06 am

NetworkNewsBreaks – EyeGate (NASDAQ: EYEG) Inks Licensing Deal with Valeant Pharmaceuticals (NYSE: VRX); Shares Higher

EyeGate Pharmaceuticals (NASDAQ: EYEG) is trading 39% higher this morning on news of its exclusive, worldwide licensing agreement with Valeant Pharmaceuticals (NYSE: VRX). Shares of Valeant are up 4%. The company has allowed a subsidiary of Valeant commercial and manufacturing rights to the EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients. Per the agreement, EyeGate received an upfront cash payment and will receive royalties on Valeant's net sales of the product. Additionally, the company may also receive development-based and sale-based milestone payments. This partnership follows a 2015…

Continue Reading

TuesdayFeb 21, 2017 10:02 am

NetworkNewsBreaks – MTBC’s (NASDAQ: MTBC) talkEHR™ Platform Receives 2015 Edition ONC Health IT Certification

Health care information technology company Medical Transcription Billing, Corp. (NASDAQ: MTBC; MTBCP) this morning announced that its voice-enabled EHR platform, talkEHR™, received 2015 Edition Health IT certification as a Health IT Module from ICSA Labs on February 3, 2017. Certification criteria related to the ONC Health IT 2015 Edition Certification Program aim to enhance privacy and security capabilities, improve patient safety and interoperability and improve upon the reliability and transparency of certified Health IT. “talkEHR 'breaks the mold' in the EHR industry by melding the advanced functionality required under Meaningful Use Stage 3 with one of the most user-friendly interfaces…

Continue Reading

TuesdayFeb 21, 2017 9:37 am

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary Set to Unveil New Partnership Program at GSMA Mobile World Congress 2017

Global payment technology provider Net Element, Inc. (NASDAQ: NETE), through subsidiary Digital Provider, this morning announced plans to introduce a new partnership aimed at content providers, mobile network operators and mobile application developers during the GMSA Mobile World Congress 2017, which is set to take place in Barcelona, Spain, from February 27 to March 2, 2017. As the world’s largest gathering for the mobile industry, the Mobile World Congress will allow Digital Provider to meet face-to-face with existing partners while providing an opportunity to open dialogues with new mobile network operators (MNOs) and potential clients. The company’s current network includes…

Continue Reading

FridayFeb 17, 2017 10:44 am

NetworkNewsBreaks – ArQule, Inc. (NASDAQ: ARQL) Shares Sink on Disappointing Liver Cancer Trial

Shares of ArQule (NASDAQ: ARQL) dropped more than 20% this morning on news that the company, along with Daiichi Sankyo Cancer Enterprise, announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving overall survival. A total of 340 patients with MET-overexpressing HCC analyzed by a validated immunohistochemical assay were randomized in the intent-to-treat population for efficacy analysis. Full results from the trial will be presented at an upcoming scientific forum. “HCC is a disease with high unmet need, especially in the second-line setting, so these results are disappointing for…

Continue Reading

ThursdayFeb 16, 2017 9:37 am

NetworkNewsBreaks – Player’s Network, Inc. (PNTV) Uplists to the OTCQB Venture Market

Diversified holding company Player’s Network, Inc. (OTCQB: PNTV) this morning announced that its common shares are now trading on the OTCQB Venture Market, effective February 16, 2017. In order to be eligible for listing on the OTCQB Venture Market, which is designed for entrepreneurial and development-stage companies, Player’s Network was required to be current in its financial reporting and undergo an annual company verification and management certification process. “We are proud to announce this corporate milestone as we execute our plan to add tenure to our 23-year track record as a fully reporting company,” Mark Bradley, CEO of Player’s Network,…

Continue Reading

ThursdayFeb 16, 2017 9:24 am

NetworkNewsBreaks – ORhub, Inc. (ORHB) Announces Engagement of NetworkNewsWire

Health care software-as-a-service company ORhub, Inc. (OTC: ORHB) this morning announced that it has engaged NetworkNewsWire (NNW), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. As part of this new client-partner relationship, NNW will leverage its investor-based Brand Network of partners, as well as a rapidly expanding distribution network of well over 5,000 key syndication outlets, to generate greater brand awareness for ORhub. “ORhub is entering into a season of acceleration, and during this time it is important that we keep the investment…

Continue Reading